Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30238240 | 0.85 | CHRNB2 (0.41) | PDE4BALDH1A1MAPTBRD4MEN1 | |
| SCHEMBL23979945 | 0.85 | ALDH1A1 (0.45) | NR1H2NAMPTALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL173439 | 0.85 | PDE4B (0.41) | PDE4BNR1H2ALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL27736427 | 0.84 | NR1H2 (0.42) | NR1H2NAMPTALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL24812373 | 0.84 | NR1H2 (0.42) | NR1H2NAMPTALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL1224464 | 0.84 | MAPT (0.48) | NR1H2NAMPTALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL30456334 | 0.84 | MAPT (0.48) | NR1H2NAMPTALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL1224468 | 0.84 | MAPT (0.48) | NR1H2NAMPTALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL2731021 | 0.81 | NR1H2 (0.38) | NR1H2NAMPTALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL21995232 | 0.81 | NR1H2 (0.39) | NR1H2NAMPTALDH1A1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3719024-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | MARS, INCORPORATED | 2020-08-06 | — | — | US | disclosed |
| EP-3034509-B1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10603330-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2019-02-21 | — | — | US | disclosed |
| US-10098902-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2018-10-16 | — | — | US | disclosed |
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2017-01-05 | — | — | US | disclosed |
| EP-3034509-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2632927-B1 | BORONATES AS ARGINASE INHIBITORS | MARS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9233985-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| EP-2632927-A1 | BORONATES AS ARGINASE INHIBITORS | Mars, Incorporated (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| WO-2012058065-A1 | BORONATES AS ARGINASE INHIBITORS | MARS INCORPORATED (US) | 2012-05-03 | — | — | WO | disclosed |
| US-7125870-B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2004043349-A2 | ISOXAZOLINE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | PDE4B 441/4885NR1H2 100/4885NAMPT 2147/4885 |
| US-10603330-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | PDE4B 441/4885NR1H2 100/4885NAMPT 2147/4885 |
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | PDE4B 441/4885NR1H2 100/4885NAMPT 2147/4885 |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | PDE4B 441/4885NR1H2 100/4885NAMPT 2147/4885 |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | ARG1, ARG2, PRMT1 | PDE4B 441/4885NR1H2 100/4885NAMPT 2147/4885 |
| US-10098902-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | PDE4B 441/4885NR1H2 100/4885NAMPT 2147/4885 |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CLPP, PRCP, PREP | PDE4B 2826/4885NR1H2 3897/4885NAMPT 1721/4885 |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP2, MMP1, MMP9 | PDE4B 1075/4885NR1H2 986/4885NAMPT 792/4885 |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | PDE4B 441/4885NR1H2 100/4885NAMPT 2147/4885 |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | PDE4B 441/4885NR1H2 100/4885NAMPT 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.